Separating the research from the marketing
"Immune-boosting" is not a measurable outcome. Immunology trials measure specific things — infection rates, viral clearance, vaccine antibody titres, cytokine levels, survival in sepsis. When a peptide is sold as "immune support", ask which of those has actually been measured in humans.
What real immune peptide research looks like
- Thymosin alpha-1 (thymalfasin) is approved in several countries (not the U.S.) for chronic hepatitis B and as a vaccine adjuvant, and has been trialled in sepsis and, more recently, in COVID-19. Its human evidence base is real, if mixed. It is a different molecule from the TB-500 sold online.
- Thymosin beta-4 has phase 1/2 trials for dermal wounds, dry eye and neurotrophic keratopathy. These are healing endpoints, not immune ones, and they concern the full 43-amino-acid peptide.
What is being sold
TB-500 is marketed as a fragment of thymosin beta-4. There are no controlled human trials of TB-500 for any immune outcome. BPC-157 has anti-inflammatory findings in rodent gut and injury models, and no human immune data. Both remain preclinical for this area.
The safety question nobody answers
Peptides that genuinely modulate immune signalling could plausibly cause harm as well as benefit — the history of immunotherapy is full of unexpected effects. The absence of human trials means the absence of safety data, not the presence of safety.
